ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM: Abstract Number: 2388

Increased Risk of Severe Infections in Early Giant Cell Arteritis: A Population- based Study

(2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

9:00AM-11:00AM: Abstract Number: 2282

Increased Risk of Systemic Lupus Erythematosus Flare After COVID-19

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2094

Increasing Collaboration, Education, and Awareness of Scleroderma Through an Interprofessional Education Program: Emphasizing the Importance of a Multidisciplinary Team and the Patient as the Primary Educator

(2089–2094) Patient Education/Community Service – Interprofessional Poster

9:00AM-11:00AM: Abstract Number: 2120

Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections

(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2229

Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies

(2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment: SpA Poster III

9:00AM-11:00AM: Abstract Number: 1743

Individuals At-risk for and with Rheumatoid Arthritis Have Elevated Fecal Concentrations of Arthritogenic Subdoligranulum didolesgii Correlating with CCP3 Antibodies

(1734–1775) RA – Etiology and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 2305

Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 1967

Infectious Myopathies in an Urban Inflammatory Idiopathic Myopathy Cohort: Frequency and Impact on Disease Course and Treatment

(1945–1972) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

9:00AM-11:00AM: Abstract Number: 2103

Inflammation and Immunomodulatory Therapies Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis

(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 1766

Inflammatory Priming of the Joints via Pre-activation of Macrophages by Anti-MAA Antibodies in Rheumatoid Arthritis

(1734–1775) RA – Etiology and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 2417

Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study

(2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

9:00AM-11:00AM: Abstract Number: 1847

Influence of Seasonal Changes on Adherence in Rheumatoid Arthritis Patients

(1840–1861) Health Services Research Poster III

9:00AM-11:00AM: Abstract Number: 1978

Infrapatellar Fat Pad Size and Subcutaneous Fat in Knee Osteoarthritis Radiographic Progression: Data from the Osteoarthritis Initiative

(1977–1995) Osteoarthritis – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2095

Integrated Analysis of Gene Expression and Methylation Identifies Biomarkers Associated with Mode of Action of Upadacitinib Treatment in Rheumatoid Arthritis

(2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 1773

Integrated Analysis of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) Transcriptome and Chromatin Accessibility Identifies Mechanisms Associated with Location-specific Disease Severity

(1734–1775) RA – Etiology and Pathogenesis Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].